NR4A1 and breast cancer: On the other hand, in hormone receptor-positive BC patients, who have already been exposed to hormone therapy but not in combination with CDK4/6 inhibitors, should PARPis be preferred over a combination of hormone therapy plus cell cycle inhibitors?